Drugmakers are hitting record highs while tech craters — buy the pharma rotation in AbbVie, Lilly and Gilead

Verdict: a credible rotation thesis with no live entry — wait for the pullback

The rotation thesis has real fundamental support on two of three names: Eli Lilly grew Q2 revenue 16.0% to $23.0B with operating cash flow doubling to $10.7B, and AbbVie's revenue rose 13.3% to $17.0B with net income jumping from $695M to $3.6B. The strongest point against is that one-third of the basket contradicts the 'real earnings' claim outright — Gilead's Q2 net loss of $10.5B pushed net margin to -134.5% and debt-to-equity from 0.94 to 2.22, and provisional September 30, 2026 filings show net open-market insider selling at all three companies (about $8.2M at ABBV, $15.2M at GILD, $2.9M at LLY). The trade itself is nowhere near actionable: the entry needs each name's daily RSI at or below 45 while price holds above the 50-day EMA, but RSI reads 75.5 at ABBV, 67.9 at GILD, and 77.3 at LLY — the setup never fired in 60 months of daily bars, and no robust parameter setup was established. So this is a watch-list, not a buy: the disciplined move is to wait for the momentum pullback the idea itself says to buy rather than chase these highs. If Gilead's next quarterly report shows the loss was a one-off (for example, a charge) and the next ownership filings stop showing net selling, the verdict flips toward action.

Trade now: the pullback hasn't arrived — wait for RSI under 45 with the uptrend intact

This is a watch-list setup, not an active signal. The entry requires each name's daily RSI (14) to dip to 45 or below, cross back above price, while price holds above its 50-day EMA and trend strength (ADX) stays above 18. Two of those four conditions are already in place — price sits above the 50-day EMA for all three names, and ADX is above 18 (ABBV at 37.4, GILD at 23.4, LLY at 22.1). What's missing is the pullback: RSI is at 75.5 for ABBV, 67.9 for GILD, and 77.3 for LLY, all far above the 45 threshold. Buying now would mean chasing exactly what the idea says not to do. Concretely, "wait" means letting each name pull back enough to cool momentum while keeping its uptrend structure. If an entry triggers, the live risk rules cap loss at 2.3% per position and take profit at 4.5%, an effective reward-to-risk of roughly 2 to 1, with position sizes capped at 25% per name. Structural exit levels also apply: a close at the nearest resistance triggers profit-taking (ABBV $269.70, GILD $157.29, LLY $1,249.45 — note GILD at $156.19 is already within a whisker of that level), and a break through the second-ranked support stops the trade out. The most likely name to trigger first is GILD, whose RSI needs only a modest cooling and whose nearest support sits at $150, about 4% below the $156.19 close. ABBV and LLY are more extended — LLY is 57% above its range low and needs the deepest retracement. No robust parameter setup was established by the sensitivity evaluation (it ran out of its time budget), so the published thresholds are used as written. Until the momentum readings come down to the trigger zone, the disciplined move is to do nothing and let the rotation pullback come to you.

Real earnings, not just rotation: the fundamentals behind the pharma bid

The idea argues that money rotating out of AI is landing in big pharma because these companies have genuine earnings and pricing power, and the latest numbers back that up on at least two of the three names. AbbVie's Q2 (period ended June 30, 2026) shows a company firing on most cylinders: revenue rose 13.3% quarter over quarter to $17.0B, net income jumped from $695M to $3.6B, net margin expanded to 21.3% from 4.6%, and gross margin improved to 74.7%. Operating margin hit 37.9%, up more than 11 percentage points in one quarter. Eli Lilly is the strongest version of the thesis. Its Q2 revenue of $23.0B was up 16.0% sequentially, gross margin reached 85.8%, and operating cash flow doubled from $5.3B to $10.7B. Against a sector panel, LLY's 42.5% year-over-year revenue growth sits around the 77th percentile of Health Care peers, and its 82.5% gross margin is around the 78th percentile — this is a franchise with pricing power, exactly what the idea claims. Lilly's dividend record reinforces it: the payout has grown at a 15.3% annual clip, from $3.40 per share in 2021 to $5.19 in 2026. AbbVie carries the cash-generation argument too. Its free cash flow ranks around the 99.5th percentile of Health Care peers, and the dividend has grown steadily ($5.20 per share in 2021 to $6.92 trailing twelve months, about 5.5% annual growth, with the latest $1.73 payment ex-dating October 15, 2026). That is the kind of durable income profile the idea says funds rebalance toward. The cited MarketWatch story from October 15, 2026 confirms the market context: big pharma trading near all-time highs as a tech selloff pushes investors toward safer bets — the entry conditions in the strategy are built for exactly that state, buying a pullback that holds above the 50-day trend rather than chasing the highs. One important framing note on the evidence: over the last 60 months (1,220 daily bars evaluated per pair, plus 24- and 12-month windows), the pullback entry rules did not trigger on ABBV, GILD, or LLY — so this is a watch-list setup, not an active signal. The research author has requested bounded expanded optimization to make the thresholds evaluable while preserving the thesis, symbols, long direction, and a final holdout. No robust parameter setup has been established yet, so the entry should be judged on thesis fit rather than any historical trade record.

A rough trip: insider selling, Gilead's loss quarter, and an entry that has never fired

The bear case starts with Gilead, which is the direct counterweight to the 'real earnings' claim. Its Q2 (ended June 30, 2026) produced a net loss of $10.5B — a swing from a $2.0B profit the prior quarter — with net margin collapsing to -134.5% and operating margin to -133.2%. Its debt-to-equity ratio jumped from 0.94 to 2.22, a 135% quarter-over-quarter increase. A fund-flow thesis built on earnings quality cannot ignore that one-third of this basket just reported one of its worst quarters on record. Even Gilead's dividend story is softer than…

Scores

• Conviction score breakdown: 48
• Thesis support: 65
• Trade readiness: 40
• Risk quality: 55
• Trigger proximity: 20
• Fundamentals trend: 60

Watch items

• ABBV — RSI (14), daily
• GILD — RSI (14), daily
• LLY — RSI (14), daily
• GILD — RSI (14) vs 70 overbought exit threshold
• ABBV — Insider net open-market activity (next ownership filing)
• GILD — Insider net open-market activity (next ownership filing)
• LLY — Debt-to-equity, next quarterly report
• ABBV — Quarterly ex-dividend date